Caffeine Doses of 3 mg/kg Increase Unilateral and Bilateral Vertical Jump Outcomes in Elite Traditional Jiu-Jitsu Athletes

Caffeine increases vertical jump, although its effects on kinetics and kinematics during different phases of bilateral and unilateral jumps remain unclear. The aim of this study was to identify the effects of 3 mg/kg on kinetic, kinematic and temporal variables in the concentric and eccentric phases of bilateral and unilateral countermovement jumps. A total of 16 Spanish national team traditional Jiu-Jitsu athletes took part in two experimental trials (3 mg/kg caffeine or placebo) in a randomized, double-blind crossover study. Sixty minutes after ingestion, bilateral and unilateral jumps were performed on a force platform. Compared to the placebo, caffeine increased bilateral jump height (p = 0.008; Δ% = 4.40), flight time (p = 0.008; Δ% = 2.20), flight time:contraction time (p = 0.029; Δ% = 8.90), concentric impulse (p = 0.018; Δ% = 1.80), peak power (p = 0.049; Δ% = 2.50), RSI-modified (p = 0.011; Δ% = 11.50) and eccentric mean braking force (p = 0.045; Δ% = 4.00). Additionally, caffeine increased unilateral RSI-mod in both legs (Left: p = 0.034; Δ% = 7.65; Right: p = 0.004; Δ% = 11.83), left leg flight time (p = 0.044; Δ% = 1.91), left leg jump height (p = 0.039; Δ% = 3.75) and right leg FT:CT (p = 0.040; Δ% = 9.72). Caffeine in a dose of 3 mg/kg BM in elite Jiu-Jitsu athletes is a recommended ergogenic aid as it increased performance of bilateral and unilateral vertical jumps. These increases were also accompanied by modified jump execution during the different phases of the countermovement prior to take-off.

Download Full-text

Concurrent validity, inter-, and intrarater reliabilities of smart device based application for measuring vertical jump performance

Baltic Journal of Health and Physical Activity ◽

10.29359/bjhpa.12.3.04 ◽

2020 ◽

Vol 12 (3) ◽

pp. 35-46

Author(s):

DONG-SIK OH ◽

YOON-HEE CHOI ◽

YU-JIN SHIM ◽

SAM-HO PARK ◽

MYUNG-MO LEE

Keyword(s):

Concurrent Validity ◽

Vertical Jump ◽

Flight Time ◽

Smart Device ◽

Portable Devices ◽

Jump Height ◽

Post Injury ◽

Jump Performance ◽

Injury Rehabilitation ◽

Vertical Jumps

Background: The aim of this study was to examine the concurrent validity and inter-and intra-rater reliabilities of smart device based application, against force platform-based portable device Wii balance board (WBB) measurements for the flight time and jump height during the vertical jump. Material and methods: Thirty participants (23.8 ±3.41 years) completed three vertical jumps, which were evaluated using WBB and application for smart device. To assess the concurrent validity, jump height and flight times were obtained from each device. Inter-and intra-rater reliabilities were determined by replicating data analysis of smart device based application recordings. Results: Flight time and jump height collected from smart device based application showed excellent agreement level with WBB (flight time and jump height: ICC [2,1]=0.972). However mean flight time and jump height from the smart device based application was significantly higher than WBB (mean difference: 0.006 sec, 0.745 cm, p < 0.05). Intra-rater sessions showed good level of agreement (flight time: ICC [2,1] = 0.967, jump height: ICC [2,1] = 0.974), and inter-rater session showed almost perfect reliability (flight time: ICC [2,1] = 0.985, jump height: ICC [2,1] = 0.987). Conclusions: Smart device-based applications could be used to replace pressure-based portable devices for clinical evaluations in post-injury rehabilitation as well as evaluating sports performance.

Download Full-text

Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

Thrombosis and Haemostasis ◽

10.1055/s-0038-1649787 ◽

1995 ◽

Vol 74 (02) ◽

pp. 622-625 ◽

Cited By ~ 29

Author(s):

H H Brackmann ◽

R Egbring ◽

A Ferster ◽

P Fondu ◽

J M Girardel ◽

...

Keyword(s):

Factor Xiii ◽

Bleeding Events ◽

Serious Adverse Events ◽

Double Blind ◽

Randomised Study ◽

The Mean ◽

Blind Crossover Study ◽

Double Blind Crossover Study ◽

Fxiii Activity ◽

Observation Period

SummaryThe pharmacokinetics and tolerability of factor XIII (FXIII) from plasma were compared with those of FXIII from placenta in a randomised, double-blind, crossover study involving 13 patients with congenital FXIII deficiency. Both FXIII activity and FXIII antigen were monitored. No difference was seen in the mean half-lives of the two preparations (9.3 days and 9.1 days for plasma and placenta FXIII activity, respectively). Response was similar for both preparations, but was slightly greater for FXIII from plasma.Similar results were found for recovery (65% vs 60%). The area under the data completed by extrapolation was significantly higher for FXIII from plasma. No differences between preparations in terms of efficacy or tolerability were observed. It can be concluded that treatment with FXIII concentrate from plasma is as efficient as with FXIII concentrate from placenta in terms of recovery and half-life. Both preparations were equivalent in terms of safety during the observation period. With the administration of monthly injections of approximately 30 U/kg serious bleeding events were prevented and no other serious adverse events occurred.

Download Full-text

Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone

Thrombosis and Haemostasis ◽

10.1055/s-0038-1666900 ◽

1979 ◽

Vol 42 (02) ◽

pp. 621-625 ◽

Cited By ~ 1

Author(s):

G G Nenci ◽

G Agnelli ◽

M Berrettini ◽

P Parise ◽

E Ballatori

Keyword(s):

Platelet Aggregation ◽

Crossover Study ◽

Double Blind ◽

Platelet Aggregability ◽

Initiation Of Therapy ◽

Spontaneous Platelet Aggregation ◽

Blind Crossover Study ◽

Double Blind Crossover Study

SummaryIn a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.

Download Full-text